Axsome stock tumbled Tuesday after Axsome Therapeutics issued mixed results for its drug, Sunosi, in ADHD treatment.

Axsome Therapeutics (NASDAQ:AXSM) announced Tuesday that solriamfetol, its experimental therapy for attention deficit ...

Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...

The 37-year-old Canadian musician, who shares three kids with Elon Musk, seemed to be grateful that she had not been ...

ADHD in adults is often overlooked. Subtle signs include time blindness, trouble staying organized, and difficulty with ...

Abruptly discontinuing your ADHD medication may cause rebound symptoms. Learn more about the rebound effect and how your ...

TikTok has become the go-to-source on ADHD for teens and young adults. But a new study finds a lot of the information is ...

An adult brain affected by attention deficit disorder with or without hyperactivity (ADHD) presents modifications similar to ...

A Trump executive order forming the commission tasked them with assessing the ‘threat posed by’ ADHD meds. Learn how experts ...

Industry leaders say the government failed to protect Thomas Cooper, 5, from dying in a hyperbaric chamber fire at the Oxford ...

A new study warns that trending ADHD content on the app may be warping perceptions, promoting products, and missing the mark ...

Investing.com -- Shares of Axsome Therapeutics (NASDAQ: AXSM) fell 5.5% following the announcement of its phase 3 trial results for Solriamfetol in adults with ADHD, which achieved its primary ...